Research programme: cartilage repair therapeutics - Sanofi/Scil Technology

Drug Profile

Research programme: cartilage repair therapeutics - Sanofi/Scil Technology

Alternative Names: CDRAP-MIA; SAR-396049; ST03; ST03A; ST03B; ST04

Latest Information Update: 07 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scil Technology
  • Developer Sanofi
  • Class
  • Mechanism of Action Intercellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cartilage disorders; Osteoarthritis

Most Recent Events

  • 07 Apr 2014 Preclinical development is ongoing in France
  • 31 Dec 2012 Preclinical trials in Osteoarthritis in France (Parenteral)
  • 20 Dec 2011 Preclinical trials in Cartilage disorders in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top